Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adults
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
A randomized, single-blind and parallel group study to compare the pharmacokinetic, safety
and immunogenicity of HS-20090-2 60mg#1ml#and Prolia® in healthy adults.